Buy & Sell Kraft Heinz Co (KHC) – Kraft Heinz Co Price Today
Aura AI Summary
Key Stats
- $27.18BMarket Cap
- Consumer StaplesSector
- -14.41%3M Drawdown
- $44.22BEnterprise Value
- 6.98%Dividend Yield
- 118 daysTypical Hold Time
Kraft Heinz Co (KHC) is currently valued at a market capitalization of $27.18B, with an enterprise value of $44.22B. Over the past 52 weeks, Kraft Heinz Co has traded between a low of $21.21 and a high of $28.94, highlighting its annual price range. Over the past three months, Kraft Heinz Co has recorded a drawdown of -14.41%, reflecting recent price volatility. Kraft Heinz Co offers a dividend yield of 6.98%, with the most recent dividend of $0.40 paid on 06 Mar 26. On average, investors hold Kraft Heinz Co for approximately 118 days, indicating typical investor behavior on the platform.
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Most Recent News
US-China deal commits China to buy $17B in US farm goods annually through 2028
President Donald Trump secured a major deal with China, where China agreed to purchase at least $17 billion worth of US agricultural products annually until 2028. This agreement was announced after a two-day summit in China, the first by a US preside...
Trump warns Iran to act fast or face severe consequences amid stalled peace talks.
Former President Donald Trump issued a stern warning to Iran, urging swift action in stalled peace negotiations or face severe consequences. He rejected Iran's demand to separate nuclear talks from peace discussions, emphasizing that time is critical...
Pluvicto plus standard care cuts PSA progression risk by 58% in metastatic hormone-sensitive prostate cancer.
Novartis announced that combining Pluvicto (lutetium-177 vipivotide tetraxetan) with standard care (ARPI + ADT) significantly improves PSA response in metastatic hormone-sensitive prostate cancer (mHSPC), reducing PSA progression risk by 58% compared...
